Anti-angiogenic compound and usage thereof

A technique for inhibiting angiogenesis and compound, which is applied in the field of medicine and achieves the effects of high safety, wide source of raw materials and low price

Active Publication Date: 2015-06-17
HANGZHOU LEISUO PHARMA +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] So far, there have been no relevant re...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-angiogenic compound and usage thereof
  • Anti-angiogenic compound and usage thereof
  • Anti-angiogenic compound and usage thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 Qualitative observation of the inhibitory effect of Closantel on the generation model of zebrafish body intersegmental vessels (ISV)

[0046] Zebrafish:

[0047] The zebrafish used in this example is vascular transgenic green fluorescent zebrafish (a gene specifically expressed by zebrafish endothelial cells acts as a driver to drive the specific expression of green fluorescent protein in zebrafish vascular endothelial cells) ( figure 1 ), the feeding and use standards were strictly in accordance with the requirements of the American Institutional Animal Care and Use Committee (IACUC).

[0048] Fish water:

[0049] Configuration method: add 0.3g of sea salt (InstantOcean salts) to 1L of reverse osmosis (RO) water.

[0050] Dimethyl sulfoxide (DMSO, analytically pure):

[0051] Purchased from Aladdin (Catalog #1095515, Lot #30573). 0.1% DMSO solution (negative control) preparation: when in use, use fish culture water to prepare a working solution with a con...

Embodiment 2

[0061] Example 2 Quantitative evaluation of the inhibitory effect of Closantel on the generation model of zebrafish intersegmental vessels (ISV)

[0062] The budding of zebrafish vascular endothelial cells starts at 20hpf after fertilization, forms the main intersegmental vascular network at about 30-31hpf, such as dorsal long axis vessels (DLAV) and intersegmental vessels (ISV), and basically forms a complete body axis at 48hpf Vascular network [17] , the intact intersegmental vessels (ISVs) are clearly visible at this time. The complete intersegmental vessel mainly refers to the segment of vessel connecting the dorsal aorta (DA) and the dorsal long axis vessel (DLAV), see figure 1 (48hpf vascular transgenic fluorescent zebrafish body intersegmental vessel model). There are 28 pairs of intact intersegmental vessels (ISVs) in 48hpf zebrafish. The experimental method is as follows:

[0063] (1) Experimental grouping and embryo treatment: 300 well-developed zebrafish embryos...

Embodiment 3

[0071] Example 3 Quantitative evaluation of the inhibitory effect of Closantel on the zebrafish inferior intestinal vessel (SIV) generation model

[0072] Zebrafish subintestinal vessel (SIV, subintestinal vessel) grows on both sides of the yolk sac, and its shape is like a basket. The length of the subintestinal vessel (SIV) extending downward from the ventral side of the somites is about 50-100 μm [15-16] . See Figure 5 (72hpf vascular transgenic fluorescent zebrafish subintestinal vascular model). The experimental method is as follows:

[0073] (1) Experimental grouping and embryo treatment: 120 well-developed zebrafish embryos were taken, and the embryo development phase was 48hpf (hour-postfertilization, hpf) after fertilization, and were randomly divided into 4 groups, as shown in the following table:

[0074]

[0075] The number of zebrafish embryos in each group was 30. During the operation, the embryos were evenly distributed to 48-well cell culture plates (Gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an anti-angiogenic compound and usage thereof. A generative model of zebra fish blood vessels is used for carrying out an internal pharmacodynamic experiment confirmation. The compound can obviously restrain the blood vessels angiogenesis of the zebra fish. Therefore, the compound can be used for preparing the anti-angiogenic drugs, anti-tumor effect drugs and senile macular degeneration drugs.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an anti-angiogenesis compound and its application. Background technique [0002] Angiogenesis is highly related to many major human diseases, such as malignant tumors, age-related macular degeneration (Age-related macular degeneration, AMD), atherosclerosis (Atherosclerosis), rheumatoid arthritis (Rheumatoid arthritis), diabetes Retinal degeneration (Diabeticretinopathy) and tumor metastasis (Tumor metastasis), etc. [1] . With the gradual increase of the aging population in China, these major diseases have seriously endangered the life and health of the people of our country. [0003] In 1971, Professor Judah Folkman of Harvard University proposed anti-tumor blood vessel therapy for the first time. He believed that the growth and spread of solid tumors depended on the formation of new blood vessels in the tumor and obtained nutrients through the new blood vessels; the formatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/277A61P35/00A61P27/02
Inventor 李春启吴转斌朱晓宇朱凤
Owner HANGZHOU LEISUO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap